Tumor Biology Drives Personalized Surgical Interventions in Breast Cancer
September 17th 2019Shubhada Dhage, MD, FACS, discusses the role of surgery and other therapeutic modalities in breast cancer and explained the shift toward de-escalated treatments and less morbid surgical management strategies.
Dr. Adams on Combinatorial Approaches in Triple-Negative Breast Cancer
August 1st 2018Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, NYU Langone’s Perlmutter Cancer Center, discusses combinatorial approaches in triple-negative breast cancer.
Dr. Adams on Immunotherapy in Triple-Negative Breast Cancer
July 3rd 2018Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, New York University Langone’s Perlmutter Cancer Center, discusses immunotherapy in triple-negative breast cancer (TNBC).
Dr. Majure on Unmet Needs for Patients With TNBC
November 8th 2017Melanie C. Majure, MD, assistant clinical professor in the Division of Hematology/Oncology and breast oncologist, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses unmet needs for patients with triple-negative breast cancer (TNBC).
Dr. Rugo on Hormone Therapy for Patients With Breast Cancer
November 7th 2017Hope S. Rugo MD, professor of medicine and director of breast oncology and clinical trials education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses hormone therapy for patients with breast cancer.
Dr. Burris on the Potential of PARP Inhibitors in TNBC
October 24th 2017Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the potential of PARP inhibitors in patients with triple negative breast cancer (TNBC).